N
Live / Applied — First extension granted (statement of use) (as of 21 Nov 2025)
What this means for you
Not registered yet, but its 06 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98738218
- Mark type
- Design + words
- Filed
- 06 Sept 2024
- Published for opposition
- 15 Apr 2025
- Attorney of record
- Gazal Pour-Moezzi
Goods and services
- Class 005 — Pharmaceuticals: Biological and pharmaceutical preparations for the treatment of cancer and immune-related disorders
- Class 042 — Scientific and technological services: Research and development in the pharmaceutical and biotechnology fields
Owner
- Nurix Therapeutics, Inc., Brisbane, CA, US
- Nurix Therapeutics, Inc., San Francisco, CA, US
Prosecution history
- 25 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 25 Nov 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 21 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Nov 2025 — SOU EXTENSION 1 GRANTED
- 20 Nov 2025 — SOU EXTENSION 1 FILED
- 20 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Apr 2025 — PUBLISHED FOR OPPOSITION
- 09 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Mar 2025 — EXAMINER'S AMENDMENT ENTERED
- 19 Mar 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 19 Mar 2025 — EXAMINERS AMENDMENT E-MAILED
- 19 Mar 2025 — EXAMINERS AMENDMENT -WRITTEN